Onset failure is a mechanistic PK→PD construct describing a modeled situation in which the rising concentration trajectory does not reach a defined PD-relevant region within the expected modeled interval. The process begins with dissolution, which establishes the timing of material available for absorption. Gastric emptying can shift that input, while suppressed absorption reduces the rate at which systemic concentration rises. Distribution delays can further separate plasma concentration from concentration in a relevant modeled compartment, and metabolic competition can increase removal relative to accumulation. Together, these processes can flatten, delay, or truncate the rising-phase trajectory so that threshold-region crossing is not represented within the specified interval. Onset failure therefore describes a geometric property of the model rather than a clinical effect. For sildenafil, it emerges when upstream PK parameters prevent the modeled concentration from entering the PD-relevant region during the defined observation window. See onset difference.
Absorption suppression is the principal upstream mechanism for modeled onset failure because systemic input determines the slope and curvature of the early concentration trajectory. A substantially reduced absorption rate produces a flatter rising phase, extending the time required for concentration to approach a defined PD-relevant region. Delayed gastric emptying can postpone dissolution and intestinal transfer, while food-related changes can alter the timing and extent of available input. A fatty meal can therefore be represented as an upstream perturbation of dissolution-to-absorption timing rather than as a separate onset mechanism. Distribution lag adds a compartmental timing component, potentially delaying the appearance of concentration in the compartment connected to the PD model. Metabolic competition can increase removal relative to ongoing input, reducing net accumulation and changing the trajectory around peak formation. The resulting onset-failure geometry is therefore generated by interacting absorption, distribution, and removal parameters rather than by one isolated downstream event. See absorption curves and fatty food delay.
PK→PD coupling determines whether a concentration trajectory that approaches a PD-relevant region actually crosses the modeled boundary within the defined interval. Variability in the PD mapping can shift that boundary, so identical PK trajectories may produce different modeled onset coordinates depending on the concentration–effect parameters. Conversely, a suppressed PK trajectory may remain below the relevant region even when the PD mapping is unchanged. This makes onset failure a coupled geometric condition involving both concentration generation and concentration-to-effect translation. Tadalafil's longer persistence changes the later portion of its concentration–time trajectory after peak formation, but it does not redefine the upstream determinants of onset-failure geometry. The rising phase remains governed by input and absorption, with distribution and removal modifying the trajectory that reaches the PD model. Duration instead describes the later persistence of concentration after peak formation. Onset failure is therefore a parameter-alignment outcome within a PK→PD model, not a clinical failure. See pkpd onset drivers and duration vs onset balance.
Dissolution timing establishes when dissolved material becomes available for subsequent absorption, while gastric emptying and intestinal transfer determine when that material reaches the relevant absorptive environment. If either upstream process is delayed, systemic input can begin later or become distributed over a longer interval. Reduced absorption rate then flattens the rising-phase concentration curve, lowering its slope and extending the interval required for concentration to approach a defined PD-relevant region. In a modeled onset-failure case, the curve may remain below that region throughout the specified observation window. The important geometric feature is not a separate failure mechanism but insufficient upward displacement of the concentration trajectory within the available time. Changes in available input can also reduce the eventual peak magnitude, further altering the relationship between the rising trajectory and the PD-relevant region. Thus, dissolution, gastric handling, and absorption rate form an upstream timing system that can determine whether threshold-region crossing appears within the modeled interval. See absorption curves.
Absorption suppression propagates into peak geometry because the timing and magnitude of systemic input influence both Tmax and Cmax. A slower absorption process can extend the rising phase, moving Tmax later as concentration continues accumulating for a longer interval before net removal dominates. Reduced available input can also lower Cmax, decreasing the vertical extent of the trajectory relative to a defined PD-relevant region. These changes can reinforce onset-failure geometry when the rising curve approaches the region slowly and the eventual peak remains comparatively low. Tmax therefore provides a temporal marker for how long accumulation persists, while Cmax provides a magnitude marker for how far the trajectory rises. Neither parameter independently defines onset failure; both reflect the upstream interaction between input and removal. In a sildenafil model, absorption suppression can consequently shift the peak and alter its magnitude while simultaneously delaying or eliminating modeled threshold-region crossing within the selected interval. The complete geometry remains determined by the evolving concentration curve rather than by a fixed onset parameter. See absorption rate.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption Suppression | Flattened rising-phase. | absorption curves |
| Absorption → Tmax/Cmax | Peak geometry shift. | absorption rate |
Gastric emptying is an upstream timing variable because it determines when material leaves the stomach and becomes available for subsequent dissolution, transfer, and absorption. A delayed emptying process can shift the entire input function to the right on the time axis, producing a later start or broader distribution of systemic input. If absorption then occurs over a similar or reduced rate range, the resulting concentration trajectory can rise too slowly to enter the defined PD-relevant region within the modeled interval. The effect is therefore represented as a change in input timing rather than a new pharmacodynamic mechanism. Gastric delay can also reposition Tmax because the peak is generated downstream of the delayed input. If the delayed input is accompanied by reduced systemic availability, Cmax can change as well, further altering the vertical geometry of the profile. In onset-failure modeling, gastric handling is therefore an upstream transformation of the input function that can shift the complete concentration–time trajectory. See gastric emptying.
Food-related variation can modify the timing and shape of the absorption input function. A fatty meal can be represented mechanistically as a condition that changes gastric handling and delays the appearance of absorbable material, while meal timing can alter the temporal relationship between food exposure and drug input. These changes can shift the rising phase, flatten its initial slope, or move the concentration trajectory later along the time axis. Food-related variability can therefore produce different Tmax and Cmax geometries without requiring a distinct onset mechanism. In a modeled sildenafil profile, the resulting effect depends on how the altered input function interacts with absorption and removal parameters. A delayed input combined with slow absorption can extend the rising phase substantially, while a change in available input can modify peak magnitude. The onset-failure condition occurs when the resulting trajectory does not enter the defined PD-relevant region within the specified interval. Food is therefore represented as an upstream modifier of PK geometry rather than as a direct PD determinant. See food impact and fatty food delay.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Gastric Emptying Delay | Upstream timing. | gastric emptying |
| Food Interaction | Absorption timing. | food impact |
Distribution delays modify onset-failure geometry by changing the temporal relationship between plasma concentration and concentration represented in a relevant model compartment. After systemic entry, movement between compartments occurs according to transfer parameters. Slower equilibration can create a larger time separation between the central concentration trajectory and the concentration used by the downstream PK→PD model. Consequently, a plasma trajectory may rise while the modeled target compartment remains below its defined PD-relevant region. The resulting timing difference is a distribution effect rather than an absorption effect. Distribution can also interact with a flattened absorption curve: when systemic input is already delayed, additional compartmental equilibration time can further shift the modeled concentration trajectory. The combined profile may therefore show a later or incomplete threshold-region crossing within the selected observation interval. In this framework, distribution does not independently determine whether systemic concentration exists; it determines how that concentration is temporally represented across modeled compartments. Distribution variability consequently acts as a secondary modifier of onset-failure geometry after systemic input has been established. See pk variability.
Metabolic competition changes onset-failure geometry by modifying concentration removal relative to continuing systemic input. When metabolic turnover increases, concentration can be removed more rapidly while absorption is still supplying the system. This reduces net accumulation and can flatten the later portion of the rising phase or accelerate transition toward decline. If removal offsets input sufficiently, the concentration trajectory may remain below a defined PD-relevant region during the modeled interval. The interaction is especially important when absorption is already delayed or suppressed because reduced input provides less concentration accumulation to offset removal. Distribution can further modify the timing at which the remaining concentration appears in a relevant compartment. Thus, metabolic competition does not create an independent onset-failure pathway; it changes the balance between input and removal within the existing PK system. The resulting trajectory can have altered Tmax, Cmax, and curvature, with the PK→PD model determining whether the modified exposure crosses the specified region. See pd variability.
| Domain | Mechanistic Determinant | Link |
|---|---|---|
| Distribution Delay | Compartmental timing. | pk variability |
| Metabolic Competition | Early decline. | pd variability |
PK→PD coupling determines onset-failure geometry by mapping the evolving concentration trajectory onto a defined pharmacodynamic region. A suppressed absorption profile may generate a shallow rising curve, while distribution delay can shift the concentration represented in the relevant compartment and metabolic competition can increase removal. The resulting PK trajectory is then evaluated against the concentration–effect relationship. If the trajectory does not cross the defined PD-relevant boundary within the modeled interval, onset failure is represented mathematically as an absence of threshold-region crossing. The boundary itself is part of the coupling model, not an intrinsic clock time. Consequently, identical PK profiles can have different modeled transition coordinates if the concentration–effect parameters differ, while different PK profiles can converge on similar coordinates if their trajectories intersect the same PD region at similar times. The onset-failure condition therefore emerges from the interaction between exposure geometry and the PD mapping. It is a property of the coupled model rather than an independent PK parameter. See pkpd onset drivers.
PD variability can alter modeled onset failure even when the underlying PK trajectory is identical. If the concentration–effect relationship changes, the concentration required to enter the defined PD-relevant region can shift. A fixed concentration–time curve may therefore cross one modeled boundary but remain below another throughout the specified interval. In this representation, the PK trajectory has not failed to rise; rather, the PD mapping places the relevant region at a different concentration coordinate. Conversely, two different PK trajectories can produce the same modeled onset coordinate when their respective curves intersect their corresponding PD regions at equivalent times. This separates PK-driven onset failure from PD-driven threshold displacement. PK parameters determine the concentration trajectory, while PD parameters determine how that trajectory is interpreted within the concentration–effect model. The resulting onset-failure geometry is therefore sensitive to both sides of the coupling relationship. A complete mechanistic representation must distinguish changes in concentration formation from changes in the concentration–effect boundary. See pd variability.
Tadalafil's persistence modifies the later concentration–time trajectory but does not redefine the upstream determinants of onset-failure geometry. Onset remains associated with the rising trajectory approaching a specified PD-relevant region, whereas persistence describes the subsequent portion of the profile after peak formation. A slower post-peak decline can extend the duration of the modeled exposure trajectory, but it does not by itself correct or create the upstream absorption geometry. If dissolution is delayed, gastric emptying is prolonged, absorption is suppressed, distribution is delayed, or metabolic removal offsets input, the rising-phase trajectory remains governed by those parameters. The later persistence of concentration can change the shape of the complete profile without changing which upstream process generated the initial timing shift. Therefore, duration and onset failure occupy different dimensions within the same PK→PD representation. Tadalafil can have a longer later trajectory while the onset coordinate remains determined by input, absorption, distribution, removal, and PD mapping. Duration modifies temporal context rather than redefining onset-failure determinants. See duration vs onset balance.
| Variability Domain | Mechanistic Determinant | Link |
|---|---|---|
| PK Determinants | Exposure geometry. | pkpd onset drivers |
| PD Determinants | Effect mapping. | pd variability |
| Duration Interaction | Later trajectory. | duration vs onset balance |
Sildenafil onset failure can be represented when a modeled concentration trajectory does not enter a defined PD-relevant region within a specified interval. Several PK processes can produce this geometry. Delayed dissolution or gastric emptying can shift the systemic input function later. Suppressed absorption can flatten the rising phase, reducing the rate of concentration accumulation. Distribution delays can postpone concentration appearance in a compartment connected to the PD model. Metabolic competition can increase removal relative to ongoing input, limiting accumulation or accelerating the transition toward decline. These factors can operate independently or interact, producing a trajectory that remains below the defined region. The final condition is determined through PK→PD coupling, because the concentration–effect mapping establishes the boundary used to identify the modeled transition. Onset failure is therefore an emergent timing condition within the model.
Absorption suppression influences onset failure by reducing the rate at which systemic concentration increases during the rising phase. When the absorption input is slower, the concentration trajectory becomes flatter and requires more time to reach any specified PD-relevant concentration region. If the observation interval ends before the trajectory reaches that region, the model represents an onset-failure condition. Reduced absorption can also affect Cmax and Tmax because peak formation depends on the balance between continuing input and concentration removal. A delayed or flattened input profile can therefore shift the peak later, reduce its magnitude, or change the curvature surrounding the peak. These changes do not constitute separate failure mechanisms; they are consequences of altered input geometry. Absorption suppression is consequently an upstream PK determinant that can prevent threshold-region crossing within a defined modeled interval.
Gastric conditions can contribute to modeled onset failure by changing the timing of material entering the downstream absorption process. Delayed gastric emptying shifts the input function later, which can postpone dissolution, intestinal transfer, and systemic absorption. Food-related conditions can similarly modify the timing or extent of available input, producing a concentration trajectory that begins later or rises more gradually. A delayed input can move Tmax along the time axis, while altered available input can change Cmax and the vertical position of the trajectory. If the resulting rising phase does not reach the defined PD-relevant region within the selected interval, the model represents onset failure. The mechanism remains upstream PK modulation: gastric handling changes when and how much material becomes available for absorption. The PD model subsequently determines whether the resulting concentration trajectory crosses the specified boundary.
Distribution modifies onset-failure geometry by changing the timing relationship between plasma concentration and concentration in a relevant modeled compartment. Slower equilibration can delay the appearance of concentration in that compartment even while plasma concentration is already increasing. Metabolism modifies the same geometry through concentration removal. Greater metabolic turnover can offset ongoing absorption, reducing net accumulation or accelerating the transition from rising to declining concentration. These processes interact with absorption: when systemic input is already delayed or suppressed, additional distribution lag or faster removal can further reduce the upward displacement of the relevant trajectory. The combined result may be a curve that remains below the defined PD-relevant region during the modeled interval. Distribution and metabolism therefore act as secondary PK modifiers of onset-failure geometry, while the final threshold condition is established by the PK→PD coupling function.
PK→PD coupling generates onset-failure conditions by comparing a concentration trajectory with a defined concentration–effect region. The PK component determines the trajectory through absorption, distribution, and removal. The PD component determines how concentration maps onto the modeled pharmacodynamic dimension and therefore where the relevant boundary is located. If the PK trajectory remains below that boundary throughout the specified interval, no modeled onset crossing occurs. A different PD mapping could shift the boundary and change the classification of the same PK trajectory without changing any PK parameter. Conversely, a change in absorption or metabolism can alter the trajectory while leaving the PD mapping fixed. Onset failure is therefore not determined solely by concentration magnitude or solely by timing. It results from their relationship within the coupled model. The condition is best represented as a failure of threshold-region intersection during the defined interval.